glp-1 agonists with cardiovascular benefit in Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Discover the Game-Changing Benefits of
Description
What does the new JAMA study say about the link between Wegovy and NAION
doi: 10.1016/S0140-6736(24)00351-9
13 Classification of the drugs is based on the benefits of clinical studies (Table 2)
PMC12536186 5 Linge J, Birkenfeld AL, Neeland IJ
Pricing does not reflect cash price
In doing so, theyd be following in the footsteps of competitor Novo Nordisk, which received approval for its type 2 diabetes drug semaglutide (Ozempic) as a weight loss drug (Wegovy) in 2021
